Date of Award
4-24-2020
Document Type
Open Access Thesis
Degree Name
Master of Medical Science (MMSc)
First Advisor
Jeffrey Turner, MD
Abstract
Chronic kidney disease is a serious illness that reduces the life span and quality of life in diagnosed patients. Despite advancements in medical management, progression to end-stage renal disease persists. While the renoprotective effects of sodium-glucose cotransporter-2 inhibitors in diabetes mellitus patients are well-documented, no studies have examined the efficacy of these drugs in treating renal disease in the absence of diabetes mellitus. The objective of this trial is to determine whether canagliflozin, a sodium-glucose cotransporter-2 inhibitor, can improve renal outcomes in patients with non-diabetic chronic kidney disease. Utilizing a double-blind, randomized control trial design, we will examine the effects of canagliflozin on patients’ glomerular filtration rate and progression to end-stage renal disease. We hypothesize that adding canagliflozin to the standard of care, including a maximum tolerated labeled dose of an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, will decrease the mean glomerular filtration rate decline per year.
Recommended Citation
Wigley, Mia Bronte, "Canagliflozin To Slow Renal Insufficiency Progression in Non-Diabetic Chronic Kidney Disease" (2020). Yale School of Medicine Physician Associate Program Theses. 35.
https://elischolar.library.yale.edu/ysmpa_theses/35
This Article is Open Access